Key facts
- This page summarizes Joseph Press's Form 4 filing for Raphael Pharmaceutical Inc. (RAPH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Mar 2023, 16:02.
Joseph Press - 26 Jul 2022 Form 4 Insider Report for Raphael Pharmaceutical Inc. (RAPH)
- Reporting relationship
- Director
- Issuer ticker
- RAPH
- Reported as of
- 26 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2023, 16:02:36 UTC
- Prior SEC filing
- 19 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Press
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joseph Press filed Form 4 for Raphael Pharmaceutical Inc. (RAPH) on 13 Mar 2023.
Change
- Previous filing in this sequence was filed on 19 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RAPH
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +280,000
- Change %
- Price
- $0.000000
- Shares after
- 280,000
- Date
- 26 Jul 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RAPH
transaction
Derivative
Warrants to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +105,000
- Change %
- Price
- $0.000000
- Shares after
- 105,000
- Date
- 05 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 105,000
- Exercise price
- $1.12
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Joseph Press is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The warrants are exercisable immediately.